The performance of Bayer's (ETR:BAYN) stocks over the past few years has been largely negative, with its shares suffering a 20-year low amidst falling 2025 earnings forecasts. Stocks have seen general downturns following Q3 losses and a cautiously pessimistic outlook. The share price suffered notably after a U.S. court announced a review of the Monsanto case. Similarly, the shares were hit by a 7% drop after a failure to impress investors with the pharmaceutical giant's results. Apart from underlying business challenges, legal battles notably over Roundup, a weedkiller linked to cancer claims, continue to hound the company, pushing it to struggle and leading to significant fluctuations in the stock price. Nonetheless, some see upside potential in the stock following its Q3 earnings and there are signs of regaining investor confidence with stock soaring 11% after a key U.S. legal victory against Roundup cancer claims. Despite these glimmers of optimism, Bayer's long term performance underscores a need for faster, deeper changes. Plus further internal restructuring was welcomed by a major shareholder.
BAYER Stocks News Analytics from Mon, 29 Jan 2024 08:00:00 GMT to Thu, 28 Nov 2024 02:43:28 GMT - Rating -6 - Innovation -4 - Information 7 - Rumor -4